Regulatory agencies in three countries, including the United States, all approved lenvatinib in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma.
FDA Approvals …read more
Regulatory agencies in three countries, including the United States, all approved lenvatinib in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma.
FDA Approvals …read more